<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729114</url>
  </required_header>
  <id_info>
    <org_study_id>PRL-02-1001</org_study_id>
    <nct_id>NCT04729114</nct_id>
  </id_info>
  <brief_title>Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer</brief_title>
  <official_title>Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Propella Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Propella Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible metastatic castration-sensitive prostate cancer (mCSPC) and metastatic&#xD;
      castration-resistant prostate cancer (mCRPC) patients will be enrolled in the study. Phase 1&#xD;
      (Dose Escalation) of the study is a 3+3 design intended to identify the recommended Phase 2&#xD;
      dose. Phase 2a (Dose Expansion) will confirm the safety, tolerability and pharmacodynamic&#xD;
      effects of the recommended Phase 2 dose. All patients will receive PRL-02 as an i.m.&#xD;
      injection every 84 (+ 3 days) days. In both Phases, patients will undergo scheduled periodic&#xD;
      assessments of serum testosterone levels. All patients may remain on study unless their serum&#xD;
      testosterone is &gt;1 ng/dL on 2 sequential determinations starting on Day 21 through Day 77,&#xD;
      the development of unacceptable toxicity, patient withdrawal of consent, at the discretion of&#xD;
      the investigator or following 4 complete treatment cycles. Patients with a 2nd sequential&#xD;
      serum testosterone is &gt;1 ng/dL at Day 84 will be allowed to continue in the study at the&#xD;
      discretion of the investigator.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a 3+3 dose escalation study design with a dose expansion phase once a Phase 2 dose is identified.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Testosterone suppression</measure>
    <time_frame>Treatment</time_frame>
    <description>To determine a preliminary recommended Phase 2 dose of PRL-02 depot that provides adequate testosterone suppression over the course of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Treatment</time_frame>
    <description>Reporting of number of patients with adverse events related to study drug</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The starting dose will be 180 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 dose will be 360 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 dose will be 720 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4 dose will be 1260 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The recommended Phase 2a dose will be a dose from the cohort dose escalation phase that does not exceed the maximum tolerated dose and adequately suppresses serum testosterone (i.e., to less than or equal to 1 ng/dL) over the course of treatment. More than one dose may be selected for investigation in Phase 2a of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone decanoate</intervention_name>
    <description>PRL-02 depot (abiraterone decanoate for intramuscular injection) is a solution formulation of abiraterone decanoate at a concentration of 180 mg/mL and will be provided as a 10 mL vial containing 990 mg of abiraterone decanoate in 5.5 mL of solution.&#xD;
PRL-02 will be administered as an intramuscular injection every 84 days (+3 days)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained prior to any study-related procedure being&#xD;
             performed.&#xD;
&#xD;
          2. Male patients at least 18 years of age or older at time of consent.&#xD;
&#xD;
          3. Histological evidence of adenocarcinoma of the prostate.&#xD;
&#xD;
          4. Patients must have one of the following documented conditions:&#xD;
&#xD;
               -  Metastatic castration sensitive prostate cancer (mCSPC);&#xD;
&#xD;
               -  Castration sensitive prostate cancer (CSPC) with biochemical relapse (using the&#xD;
                  Prostate Cancer Working Group 3 [PCWG3] definition of PSA progression) of&#xD;
                  prostate cancer;&#xD;
&#xD;
               -  Castration sensitive prostate cancer (CSPC) with oligometastatic prostate cancer&#xD;
                  (e.g., Positron Emission Tomography (PET) positive);&#xD;
&#xD;
               -  Metastatic castration resistant prostate cancer (mCRPC) (only allowed in Phase 1&#xD;
                  at the discretion of the Investigator and after a dose cohort that demonstrates&#xD;
                  adequate suppression of serum testosterone is determined.)&#xD;
&#xD;
          5. Undergone orchiectomy or ongoing GnRH agonist or antagonist therapy for at least 1&#xD;
             month prior to the Screening Visit, AND a serum testosterone level &lt;50 ng/dL but &gt;2&#xD;
             ng/dL at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic castration resistant prostate cancer (mCRPC) patients more than minimally&#xD;
             symptomatic or with a reported pain score on an 11-point (0 - 10) numeric rating scale&#xD;
             of &gt;3 over the previous 7 days.&#xD;
&#xD;
          2. Known active central nervous system (CNS) metastases. Patients with CNS metastases&#xD;
             that have been treated with surgery and/or radiation therapy, who are off&#xD;
             pharmacologic doses of glucocorticoids, and who are neurologically stable are&#xD;
             eligible.&#xD;
&#xD;
          3. Clinically significant cardiac disease, defined as any of the following:&#xD;
&#xD;
               -  Clinically significant cardiac arrhythmias including bradyarrhythmia and/or&#xD;
                  subjects who require anti-arrhythmic therapy (excluding beta blockers or&#xD;
                  digoxin). Subjects with controlled atrial fibrillation are not excluded.&#xD;
&#xD;
               -  Congenital long QT syndrome&#xD;
&#xD;
               -  QTcF â‰¥450 msec at Screening.&#xD;
&#xD;
               -  History of clinically significant cardiac disease or congestive heart failure&#xD;
                  &gt;New York Heart Association Class II or left ventricular ejection fraction&#xD;
                  measurement of &lt;50% at baseline. Subjects must not have unstable angina (symptoms&#xD;
                  at rest) or new-onset angina within the last 3 months or myocardial infarction&#xD;
                  within the past 6 months.&#xD;
&#xD;
               -  Uncontrolled hypertension, defined as systolic blood pressure &gt;160 mmHg or&#xD;
                  diastolic blood pressure &gt;100 mmHg which has been confirmed by 2 successive&#xD;
                  measurements despite optimal medical management.&#xD;
&#xD;
               -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
                  (including transient ischemic attacks), deep vein thrombosis, or pulmonary&#xD;
                  embolism within the 3 months before start of study medication (except for&#xD;
                  adequately treated catheter-related venous thrombosis occurring &gt;1 month before&#xD;
                  the start of study medication).&#xD;
&#xD;
          4. Prior treatment with abiraterone, orteronel or current treatment with systemic&#xD;
             ketoconazole or any other CYP17 inhibitor.&#xD;
&#xD;
          5. Required concomitant use of strong inducers of CYP3A4 and substrates of CYP2C8 and&#xD;
             CYP2D6.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jackie Walling, MBChB, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Consulting JW, LLC/Propella Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tim Warneke, MS</last_name>
    <phone>919-397-4782</phone>
    <email>twarneke@propellatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Urology</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gladis Solis, RN</last_name>
    </contact>
    <investigator>
      <last_name>Roscoe Nelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Urology</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Johnson, CCRC</last_name>
    </contact>
    <investigator>
      <last_name>James Bailen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prutha Patel, RN</last_name>
    </contact>
    <investigator>
      <last_name>Ronald Tutrone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GU Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Mittelstedt, RN</last_name>
    </contact>
    <investigator>
      <last_name>Luke Nordquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xcancer/NM Oncology</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inna Lopatuk, RN, MSN</last_name>
    </contact>
    <investigator>
      <last_name>Jose Avitia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Sutton, RN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

